Onconews

Onconews

By onconewsMedicineHealth & Fitness
Download on the App Store

Onconews episodes

  • Omissão da radioterapia adjuvante no câncer de mama luminal A e rastreamento em mulheres canadenses de 40 a 49 anos

    AVISO:

    Quem segue o Podcast do Onconews nos streamings de áudio como o Spotfy, entre outros, deve fazer uma nova busca e passar a seguir a série que tem o logo com o fundo verde. A mudança ocorre para permitir a ampliação do alcance incluindo outros serviços como o Amazon Music.


    Referências deste episódio. O último dessa série:

    1. Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast
      2. Cancer - Timothy J. Whelan, B.M., B.Ch., Sally Smith, M.D., Sameer Parpia,
      Ph.D., Anthony W. Fyles, M.D., Anita Bane, M.B., Fei-Fei Liu, M.D., Eileen
      Rakovitch, M.D., Lynn Chang, M.D., Christiaan Stevens, M.D., Julie Bowen, M.D.,
      Sawyna Provencher, M.D., Valerie Théberge, M.D., et al., for the LUMINA Study
      Investigators*. August
      17, 2023. N Engl J Med 2023; 389:612-619. DOI: 10.1056/NEJMoa2302344 https://www.nejm.org/doi/full/10.1056/NEJMoa2302344
    2. Impact of Breast Cancer Screening on 10-Year Net
      3. Survival in Canadian Women Age 40-49 Years - Anna N. Wilkinson, MD, MSc, CCFP;
      Larry F. Ellison, MSc2; Jean-Michel Billette, PhD; and Jean M. Seely, MD, FRCPC
      - DOI: 10.1200/JCO.23.00348 Journal of Clinical Oncology - Published online
      August 04, 2023. https://ascopubs.org/doi/full/10.1200/JCO.23.00348
      22 min
    3. Upregulation do HER2 após terapia endócrina neoadjuvante no câncer de mama HR+/HER2-negativo e sobrevida em 5 Anos no estudo WSG-ADAPT-TP

      Referências: 

      1. Chaudhary
        2. LN, Jorns J, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo M, Kong A, Patten
        C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang
        Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Frequent Upregulation Of HER2
        Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After
        Short-Term Neoadjuvant Endocrine Therapy. Res Sq [Preprint]. 2023 Apr
        7:rs.3.rs-2777910. doi: 10.21203/rs.3.rs-2777910/v1. Update in: Breast Cancer
        Res Treat. 2023 Jul 17;: PMID: 37066270; PMCID: PMC10104267. https://www.researchsquare.com/article/rs-2777910/v1
      2. Harbeck
        3. N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J,
        Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just
        M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K,
        Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT
        investigators. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without
        Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early
        Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023
        Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21. PMID:
        36809046. https://ascopubs.org/doi/10.1200/JCO.22.01816

         

        --

        24 min
      3. Associação de HER2DX com pCR e sobrevida no câncer de mama HER2+ e prevalência de câncer de mama em cirurgiãs ortopédicas

        Referências:

         

        1. Villacampa G, Tung NM, Pernas S, Paré L, Bueno-Muiño C,
          2. Echavarría I, López-Tarruella S, Roche-Molina M, del Monte-Millán M,
          Marín-Aguilera M, Brasó-Maristany F, Waks AG, Pascual T, Martínez-Sáez O, Vivancos A, Conte PF, Guarneri V, Dieci MV, Griguolo G, Cortés J, Llombart-Cussac A, Muñoz M, Vidal M, Adamo B, Wolff AC, DeMichele A, Villagrasa
          P, Parker JS, Perou CM, Fernandez-Martinez A, Carey LA, Mittendorf EA, Martín
          M, Prat A, Tolaney SM, Association of HER2DX with pathological complete
          response and survival outcomes in HER2-positive breast cancer, Annals of
          Oncology (2023), doi: https://doi.org/10.1016/j.annonc.2023.05.012.
          Ou https://www.annalsofoncology.org/article/S0923-7534(23)00721-4/fulltext
        2. Chou, Loretta B. MD; Johnson, Brianna MD; Shapiro,
          3. Lauren M. MD, MS; Pun, Stephanie MD; Cannada, Lisa K. MD; Chen, Antonia F. MD,
          MBA; Valone, Lindsey C. MD; Van Nortwick, Sara S. MD; Ladd, Amy L. MD; Finlay,
          Andrea K. PhD. Increased
          Prevalence of Breast and All-cause Cancer in Female Orthopaedic Surgeons.
          JAAOS: Global Research and Reviews 6(5):e22.00031, May 2022. | DOI:
          10.5435/JAAOSGlobal-D-22-00031 https://journals.lww.com/jaaosglobal/Fulltext/2022/05000/Increased_Prevalence_of_Breast_and_All_cause.10.aspx
          25 min
        3. Desfechos e fatores prognósticos no carcinoma lobular invasivo triplo-negativo (TN) e ctDNA na doença luminal e TN

          Referências:

           

          1. Joshi, U., Budhathoki, P., Gaire, S. et al. Clinical outcomes and prognostic factors in
            2. triple-negative invasive lobular carcinoma of the breast. Breast Cancer Res
            Treat 200, 217–224 (2023). https://doi.org/10.1007/s10549-023-06959-3
            ou https://link.springer.com/article/10.1007/s10549-023-06959-3
          2. Magbanua MJM, Brown Swigart L, Ahmed Z, Sayaman RW, Renner D, Kalashnikova E,
            3. Hirst GL, Yau C, Wolf DM, Li W, Delson AL, Asare S, Liu MC, Albain K, Chien AJ,
            Forero-Torres A, Isaacs C, Nanda R, Tripathy D, Rodriguez A, Sethi H, Aleshin
            A, Rabinowitz M, Perlmutter J, Symmans WF, Yee D, Hylton NM, Esserman LJ,
            DeMichele AM, Rugo HS, van 't Veer LJ. Clinical significance and biology of circulating tumor DNA in high-risk
            early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy.
            Cancer Cell. 2023 Jun 12;41(6):1091-1102.e4. doi: 10.1016/j.ccell.2023.04.008.
            Epub 2023 May 4. PMID: 37146605. https://www.cell.com/cancer-cell/fulltext/S1535-6108(23)00134-4
            21 min
          3. Câncer de mama no ASCO 2023 – Parte 2

            Referências:

             

            1. Primary outcome analysis of the phase 3 SONIA trial (BOOG
              2. 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6
              (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+),
              HER2-negative (HER2-) advanced breast cancer (ABC). DOI:
              10.1200/JCO.2023.41.17_suppl.LBA1000 Journal of Clinical Oncology 41, no.
              17_suppl (June 10, 2023) LBA1000-LBA1000. Published online June 07, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.17_suppl.LBA1000?role=tab
            2. A randomized controlled trial comparing primary tumor
              3. resection plus systemic therapy with systemic therapy alone in metastatic
              breast cancer (PRIM-BC): Japan Clinical Oncology Group study JCOG1017. DOI:
              10.1200/JCO.2023.41.16_suppl.523 Journal of Clinical Oncology 41,
              no. 16_suppl (June 01, 2023) 523-523. Published online May 31, 2023. https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.523
              26 min
            3. Câncer de mama no ASCO 2023

              Referências:

               

              LBA500:

               Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant
              treatment in patients with HR+/HER2− early breast cancer. 

               

              LBA506: 3-year invasive disease-free

              survival (iDFS) of the strategy-based, randomized phase II PHERGain trial
              evaluating chemotherapy (CT) de-escalation in human epidermal growth factor
              receptor 2-positive (HER2[+]) early breast cancer (EBC).

               

              --

              25 min
            4. PET-CT na doença localmente avançada e dissecção de linfonodo axilar em homens com câncer de mama invasivo

              Referências: 

              1. Chung, S.H., de Geus, S.W.L., Shewmaker, G. et al. Axillary Lymph
                2. Node Dissection is Associated with Improved Survival Among Men with Invasive
                Breast Cancer and Sentinel Node Metastasis. Ann Surg Oncol (2023). https://doi.org/10.1245/s10434-023-13475-7
                ou https://link.springer.com/article/10.1245/s10434-023-13475-7
              2. Dayes IS, Metser U, Hodgson N, Parpia S, Eisen AF, George R, Blanchette P, Cil TD,
                3. Arnaout A, Chan A, Levine MN. Impact of 18F-Labeled
                Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus
                Conventional Staging in Patients With Locally Advanced Breast Cancer. J Clin
                Oncol. 2023 May 26:JCO2300249. doi: 10.1200/JCO.23.00249. Epub ahead of print. PMID:
                37235845. https://ascopubs.org/doi/abs/10.1200/JCO.23.00249
                23 min
              3. Estudos WSG-TP-II e MAINTAIN avaliam eficácia da terapia endócrina em diferentes cenários e combinações

                Referências:  

                1. Gluz O, Nitz UA, Christgen M, et al. Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs
                  2. De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/ERBB2-Positive
                  Early Breast Cancer: The Neoadjuvant WSG-TP-II Randomized Clinical
                  Trial. JAMA Oncol. Published online May 11, 2023.
                  doi:10.1001/jamaoncol.2023.0646 https://jamanetwork.com/journals/jamaoncology/article-abstract/2804892
                2. Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, Ahn H, Trivedi MS, Novik
                  3. Y, Tiersten A, Raptis G, Baer LN, Oh SY, Zelnak AB, Wisinski KB, Andreopoulou
                  E, Gradishar WJ, Stringer-Reasor E, Reid SA, O'Dea A, O'Regan R, Crew KD,
                  Hershman DL. Randomized Phase II Trial of Endocrine Therapy With or Without
                  Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in
                  Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative
                  Metastatic Breast Cancer: MAINTAIN Trial. J Clin Oncol. 2023 May 19:JCO2202392.
                  doi: 10.1200/JCO.22.02392. Epub ahead of print. PMID: 37207300. https://ascopubs.org/doi/abs/10.1200/JCO.22.02392


                  25 min
                3. Terapia endócrina para prevenção primária e secundária e adesão às recomendações de estilo de vida

                  Referências:

                  1. Endocrine Therapy for Primary and Secondary Prevention After Diagnosis of High-Risk Breast Lesions or Preinvasive Breast
                    2. Cancer - Alison Laws, MD, MPH and Rinaa S. Punglia, MD, MPH - DOI: 10.1200/JCO.23.00455 Journal of Clinical Oncology - Published online May 01,
                    2023. - PMID: 37126767 https://ascopubs.org/doi/abs/10.1200/JCO.23.00455
                  2. Cannioto RA, Attwood KM, Davis EW, et al. Adherence to Cancer Prevention Lifestyle Recommendations Before, During, and 2 Years After Treatment for High-risk Breast Cancer. JAMA Netw Open. 2023;6(5):e2311673. doi: 10.1001/jamanetworkopen.2023.11673 https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2804477

                    3.  

                     

                    --


                    25 min
                  3. Revisão do estudo monarchE e valor clínico da expressão do receptor de progesterona no câncer de mama luminal

                    Referências:

                    1. Meirson T, Goldstein DA, Gyawali B, Tannock IF. Review of the monarchE trial suggests
                      2. no evidence to support use of adjuvant abemaciclib in women with breast cancer.
                      Lancet Oncol. 2023 May 2:S1470-2045(23)00165-1. doi:
                      10.1016/S1470-2045(23)00165-1. Epub ahead of print. PMID: 37146621. https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00165-1/fulltext
                    2. Johnston
                      3. SRD, Tolaney SM, O'Shaughnessy J, Rastogi P, Harbeck N, Martin M. Review of the
                      monarchE trial suggests no evidence to support use of adjuvant abemaciclib in
                      women with breast cancer - Authors' reply. Lancet Oncol. 2023 May
                      2:S1470-2045(23)00214-0. doi: 10.1016/S1470-2045(23)00214-0. Epub ahead of
                      print. PMID: 37146620. https://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(23)00214-0.pdf
                    3. Lashen
                      4. AG, Toss MS, Mongan NP, Green AR, Rakha EA. The clinical value of progesterone
                      receptor expression in luminal breast cancer: A study of a large cohort with
                      long-term follow-up. Cancer. 2023 Apr 15;129(8):1183-1194. doi:
                      10.1002/cncr.34655. Epub 2023 Jan 18. PMID: 36653923. https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34655

                       

                      30 min

                    About Onconews

                    From the publisher's feed

                    Podcast do portal onconews.com.br